{"name":"CytoAgents, Inc.","slug":"cytoagents-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxPcTFHVm9BcnhnbWRTVzY5SFhPcnc1UUxGQjNvWWJFR1RjbUNVWnVrZEZSaENCYlFCUm10UUsyQ3RreGtBY0lTNjNWNG1pa2NnX1QtYXRYNkpjSktUX0VTT00tMWVLenpMRFdkM0VUZkNSQUlIYUlId09GUi15YzRYV0tycjR3U2FidkF5T1N0eDRjeU9lVGI2MzVTZlVEWjJXNXNTajQ0am5xWkMxZ1RHYW1zTDZGSndMSFZqa1VwX01rTGtJUHBScWNRZVJpRF9rUEJFVzlWUjhrVnJmcDE3VGtXaHBXQ2o2LTd2anc0a0taSjhzUFNSamd4QQ?oc=5","date":"2025-12-16","type":"pipeline","source":"businesswire.com","summary":"CytoAgents Appoints Dr. Johannes Wolff as Chief Medical Officer and Michael Howell as Chief Scientific Officer - businesswire.com","headline":"CytoAgents Appoints Dr. Johannes Wolff as Chief Medical Officer and Michael Howell as Chief Scientific Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxQblMyOHMxbjJ2d0JvTk9HMk9DYjNmcGRGTUYzbDhmRmRwUE44NXlMRHRDSFZGR0w5LWd4U1JLMWdacGFRNldkaHNNRFBjd2NmV1VRZ3BmNmhNQlpHUWZGVUZ5V2lQS1VRYWkxcGhWT2lEaHZBcXhyUEJMY1IxeG51SEpOSWdxVE9ubWNuSVJHaV9PQTFIRGliTkNJSkZublB3WVhpLUNfY2gtRjhrdjJ2a1d4WFNnV1R6UjBaTmVtS3NsTld4SkFBNnVwSEFQY09oTXlF?oc=5","date":"2025-12-09","type":"trial","source":"businesswire.com","summary":"CytoAgents to Present New CTO1681 Data at the ESMO Immuno-Oncology Congress 2025 - businesswire.com","headline":"CytoAgents to Present New CTO1681 Data at the ESMO Immuno-Oncology Congress 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5aTXlUS1pXeGFsb1AwSFpfT2NYUUJXaXBtWVdNQUNmQlpoRUprUEpKVDZ0STczMG91VTExdEtVRjZZLWFPWUJLTHB6elFQaUU1UGNoa3hhZXlOdEphOFJn?oc=5","date":"2025-12-05","type":"pipeline","source":"Oncodaily","summary":"CytoAgents Welcomes Chief Medical Officer Johannes Wolff - Oncodaily","headline":"CytoAgents Welcomes Chief Medical Officer Johannes Wolff","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxNUDNUMnFDT09NRVZGNThOdlVURG1zUXBQNmZqRlJ2S21GN2JGOUNBUzYyYmZMclYtd202dXZwU2hvM0p2WDMyRk9PaWxlVEhWeDhJNTdWNm9MaThpeUtuZG9jZ0ZTYTcxQkIzZFphX3V2b0Jyc0xGM0hObWFBcENVYW1uSWlsMTRvc1luWk5BOFRvOFhiQ0FGUXhoM0pYeTF1bGtQeFR5OWY4Sm1oVHgySTV1S3IxdmpUaEEwcmhJVFlZeTdONk1KbEtCWkdNS2RjTFRpZWMxNExvWTg0TlZCUF9jclB6QkJlZDBjd3c0bG93VV9VS1VMbllWX3cyYzRKZWRn?oc=5","date":"2025-10-01","type":"pipeline","source":"businesswire.com","summary":"CytoAgents Receives Fourth Grant From National Institutes of Health to Advance Research on Cytokine Release Syndrome - businesswire.com","headline":"CytoAgents Receives Fourth Grant From National Institutes of Health to Advance Research on Cytokine Release Syndrome","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxORlMxbHd4Z1lXYm51SEN5V2NVVEJLTS16N3gyS0ZUYWE2aXlsN1ExSkQ3QWVJaERjMG1lMUdwM1o1WkluS0ZaSFV6WU12djBZc0RiVVc3azJBY1hNZ1p0SE5FMjd6YjB3U1RaVGNGS0d4OUVPRmM3X3RmNE1pR1YxUVBGZWJ5TnZldkJfdjFBMmZlaHlvcmZ6RUxzY01qX1k4WGhYZXpLQS1ycWprZTdqSnA5ZmNLN0MxY1VGNDlSU0xwNmRiTEQ0U21EbUxHMVA0cjBiM2tJRmE2bnpjMl9TTzdUdGRNQnVEc1pWM0NBRG9vT3lXWTJxczZBT3lEclU?oc=5","date":"2023-05-11","type":"regulatory","source":"businesswire.com","summary":"CytoAgents Announces FDA Acceptance of IND Application for CTO1681 to Treat Cytokine Release Syndrome in Oncology - businesswire.com","headline":"CytoAgents Announces FDA Acceptance of IND Application for CTO1681 to Treat Cytokine Release Syndrome in Oncology","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}